Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy
- PMID: 12829126
- DOI: 10.1016/s0360-3016(03)00209-8
Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy
Abstract
Purpose: The purpose of this study was to examine a variety of biomarkers in carcinoma of the cervix to better characterize (1). the natural history of the disease, (2). response to radiotherapy (RT), and (3). potential for new therapeutic strategies.
Materials and methods: Fifty-five patients with Stage IB-IVA carcinoma of the cervix, treated with definitive intent RT, and on whom tumor tissue blocks were available were included in this study. Charts were reviewed for clinical parameters and disease status. Immunohistochemistry was performed for epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), CD34, topoisomerase II alpha (topo-II), and cyclooxygenase-2 (COX-2). Univariate and multivariate Cox proportional hazards modeling was performed with disease-free survival (DFS) and overall survival (OS) as the end points. Biomarkers were evaluated for correlation between various prognostic factors.
Results: In this series of 55 patients with carcinoma of the cervix treated with definitive RT, only stage was significant on univariate analysis for DFS (p < 0.0001). On univariate analysis, increasing FIGO stage (p < 0.0001) and membranous staining of EGFR (p < 0.037) indicated diminished OS. On multivariate analysis for DFS, COX-2, VEGF, and stage were significant (p = 0.012, p = 0.014, and p = 0.03, respectively), with increased expression indicating a worse prognosis. For OS, multivariate analysis revealed that VEGF, EGFR, and FIGO stage were significant (p = 0.005, p = 0.011, and p < 0.0001, respectively). Significant direct correlations were identified between VEGF and CD34 (p = 0.04), COX-2 and topo-II (p = 0.04), COX-2 and grade (p = 0.04), and tumor size and clinical stage (p = 0.04).
Conclusion: Multivariate analysis revealed that increased staining for VEGF and COX-2 indicated diminished DFS, and VEGF and EGFR identified patients at increased risk of death. A significant direct correlation between VEGF and CD34 implicates the process of angiogenesis. Topo-II is a proliferative marker and it correlated directly with COX-2, indicating that expression of COX-2 may be greater in more proliferative tumors. Increased expression of EGFR, VEGF, and COX-2 has identified patients with a worse prognosis in cancer of the cervix. These data support the investigation of therapeutics that target these proteins in carcinoma of the cervix.
Similar articles
-
Expression of HER2neu (c-erbB-2) and epidermal growth factor receptor in cervical cancer: prognostic correlation with clinical characteristics, and comparison of manual and automated imaging analysis.Gynecol Oncol. 2004 Apr;93(1):209-14. doi: 10.1016/j.ygyno.2004.01.006. Gynecol Oncol. 2004. PMID: 15047238
-
Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix.Br J Cancer. 2000 Sep;83(5):620-5. doi: 10.1054/bjoc.2000.1319. Br J Cancer. 2000. PMID: 10944602 Free PMC article.
-
Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma.Hum Pathol. 2002 Jul;33(7):708-14. doi: 10.1053/hupa.2002.125376. Hum Pathol. 2002. PMID: 12196922
-
Cyclooxygenase-2: a therapeutic target in angiogenesis.Trends Mol Med. 2003 Feb;9(2):73-8. doi: 10.1016/s1471-4914(02)00011-4. Trends Mol Med. 2003. PMID: 12615041 Review.
-
Prognostic relevance of angiogenic, proliferative, and apoptotic factors in lung carcinomas. A case review.Methods Mol Med. 2003;74:269-82. doi: 10.1385/1-59259-323-2:269. Methods Mol Med. 2003. PMID: 12415702 Review. No abstract available.
Cited by
-
Recurrent or primary metastatic cervical cancer: current and future treatments.ESMO Open. 2022 Oct;7(5):100579. doi: 10.1016/j.esmoop.2022.100579. Epub 2022 Sep 13. ESMO Open. 2022. PMID: 36108558 Free PMC article. Review.
-
Efficacy and Safety of Apatinib for the Treatment of Advanced or Recurrent Cervical Cancer: A Single-Arm Meta-Analysis Among Chinese Patients.Front Pharmacol. 2022 Aug 11;13:843905. doi: 10.3389/fphar.2022.843905. eCollection 2022. Front Pharmacol. 2022. PMID: 36034824 Free PMC article.
-
Comparison of epidermal growth factor receptor (EGFR) and cyclooxygenase-2 (COX-2) immunohistochemical expression and outcomes in canine nasal carcinomas treated with radiation therapy.J Vet Med Sci. 2022 Sep 5;84(9):1237-1243. doi: 10.1292/jvms.22-0106. Epub 2022 Jul 15. J Vet Med Sci. 2022. PMID: 35851267 Free PMC article.
-
Pharmacological inhibition of epidermal growth factor receptor attenuates intracranial aneurysm formation by modulating the phenotype of vascular smooth muscle cells.CNS Neurosci Ther. 2022 Jan;28(1):64-76. doi: 10.1111/cns.13735. Epub 2021 Nov 2. CNS Neurosci Ther. 2022. PMID: 34729926 Free PMC article.
-
Validation of Potential Protein Markers Predicting Chemoradioresistance in Early Cervical Cancer by Immunohistochemistry.Front Oncol. 2021 Jul 19;11:665595. doi: 10.3389/fonc.2021.665595. eCollection 2021. Front Oncol. 2021. PMID: 34350111 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
